GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xintela AB (OSTO:XINT) » Definitions » Additional Paid-In Capital

Xintela AB (OSTO:XINT) Additional Paid-In Capital : kr350.38 Mil(As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Xintela AB Additional Paid-In Capital?


Xintela AB's quarterly additional paid-in capital increased from Mar. 2024 (kr349.93 Mil) to Jun. 2024 (kr350.38 Mil) but then stayed the same from Jun. 2024 (kr350.38 Mil) to Sep. 2024 (kr350.38 Mil).

Xintela AB's annual additional paid-in capital increased from Dec. 2021 (kr242.71 Mil) to Dec. 2022 (kr305.92 Mil) and increased from Dec. 2022 (kr305.92 Mil) to Dec. 2023 (kr349.93 Mil).

Xintela AB Additional Paid-In Capital Historical Data

The historical data trend for Xintela AB's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xintela AB Additional Paid-In Capital Chart

Xintela AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 140.89 208.44 242.71 305.92 349.93

Xintela AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 343.99 349.93 349.93 350.38 350.38

Xintela AB Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Xintela AB Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Xintela AB's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Xintela AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xintela AB (OSTO:XINT) » Definitions » Additional Paid-In Capital
Comparable Companies
OSTO:CLBIO OSTO:XBRANE OSTO:NXTCL OSTO:MVIR OSTO:GUARD XSAT:CESSA OSTO:ISOFOL OSTO:KDEV NGM:GTAB B OSTO:ALZ VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
1XT:Germany
Address
Medicon Village, Lund, SWE, 22381
Website
https://www.xintela.se
Xintela AB is a biomedical company that develops stem cell-based treatments with a focus on osteoarthritis and hard-to-heal leg wounds as well as, through the wholly-owned subsidiary Targinta, targeted antibody-based treatments for aggressive cancers such as triple-negative breast cancer and the brain tumor glioblastoma.

Xintela AB Headlines

No Headlines